Bevacizumab and Bortezomib in Patients With Advanced Malignancy
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of Avastin™
(bevacizumab) and Velcade™ (bortezomib) that can be given in combination to patients with a
metastatic or unresectable advanced malignancy. The safety and effectiveness of this drug
combination will also be studied.